载药微球加载贝伐珠单抗介入栓塞治疗兔VX2肝癌的抗血管生成效果  

The anti-angiogenesis effect of interventional embolization using drug-loaded microspheres with bevacizumab in treating rabbit VX2 hepatocellular carcinoma

作　　者：姚远方 高飞[1] 张雪松[1] 王魁阳 隋成旭 张亮[1] 吴杰[1] 宋磊[1] YAO Yuanfang;GAO Fei;ZHANG Xuesong;WANG Kuiyang;SUI Chengxu;ZHANG Liang;WU Jie;SONG Lei(Department of Intervention,Second ffilited Hospital of Dalian Medical University,Dalian,Liaoning Province 116027,China)

机构地区：[1]大连医科大学附属第二医院综合介入科,辽宁116027

出　　处：《介入放射学杂志》2021年第3期254-257,共4页Journal of Interventional Radiology

基　　金：辽宁省大连市医学科学研究计划项目(1712047)。

摘　　要：目的探讨载药微球加载贝伐珠单抗经导管动脉化疗栓塞(TACE)治疗兔VX2肝癌模型的抗血管生成效果。方法构建30只新西兰大白兔VX2肝癌模型,随机分为HepaSphere载药微球加载贝伐珠单抗组(A组,n=10)、Embosphere微球联合贝伐珠单抗组(B组,n=10)、单纯HepaSphere载药微球组(C组,n=10)。酶联免疫吸附试验(ELISA)法定量检测TACE术前1 d,术后1、7、14 d各组血清血管内皮细胞生长因子(VEGF)水平,术前1 d、术后14 d腹部MRI检测各组肿瘤直径,计算瘤体体积和肿瘤增长率。结果术后7 d A组、B组血清VEGF水平与C组相比均较低(P<0.05),且A组低于B组;术后14 d 3组血清VEGF水平两两比较差异均有统计学意义(P<0.05),A组最低,C组最高。术后14 d 3组肿瘤增长率两两比较差异均有统计学意义(P<0.05),A组最低。结论载药微球加载贝伐珠单抗TACE治疗可明显降低兔VX2肝癌模型术后血清VEGF水平和肿瘤增长率,疗效优于单纯载药微球或栓塞微球联合贝伐珠单抗治疗。Objective To evaluate the anti-angiogenesis effect of transcatheter arterial chemoem-bolization(TACE)by using drug-bearing microspheres loaded with bevacizumab in treating rabbit VX2 hepatocellular carcinoma(HCC).Methods VX2 HCC model was established in 30 New Zealand white rabbits.The experimental rabbits were randomly and equally divided into drug-bearing microspheres(HepaSphere)loaded with bevacizumab group(group A,n=10),Embosphere microspheres combined with bevacizumab group(group B,n=10),and simple HepaSphere microspheres group(group C,n=10).Enzyme linked immunosorbent assay(ELISA)was used to quantitatively test the preoperative 1-day and postoperative 1-day,7-day,14-day serum vascular endothelial growth factor(VEGF)levels.Abdominal MRI was performed at one day before and 14 days after the treatment to measure the tumor diameters and to calculate the tumor volume and tumor growth rate.Results The postoperative 7-day serum VEGF level in both group A and group B was lower than that in group C(P<0.05),which in group A was lower than that in group B.The differences in postoperative 14-day serum VEGF level between each other among the three groups were statistically significant(P<0.05),which was lowest in group A and highest in group C.Statistically significant differences in postoperative 14-day tumor growth rate existed between each other among the three groups(P<0.05),which was lowest in group A.Conclusion In treating rabbit VX2 HCC,TACE by using drug-bearing microspheres(HepaSphere)loaded with bevacizumab can remarkably decrease postoperative serum VEGF level and tumor growth rate in rabbit VX2 HCC models and its curative effect is superior to simple HepaSphere microspheres as well as to Embosphere microspheres combined with bevacizumab.(J Intervent Radiol,2021,30:254-257).

关 键 词：载药微球 贝伐珠单抗 经导管动脉化疗栓塞术 兔VX2肝癌模型 血管内皮细胞生长因子 

分 类 号：R735.7[医药卫生—肿瘤]